In this edition of The Motley Fool's health-care show Market Checkup, health-care analysts David Williamson and Max Macaluso take a close look at one of the largest pharmaceutical companies in the world: Bristol-Myers Squibb. This drugmaker posted results in line with analyst estimates last quarter, but what was behind it's massive year-over-year decline in revenue? What are the reasons to buy and sell this stock today? What should investors be watching in upcoming quarters? Watch today's show to find out what our analysts think.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Market Checkup: An In-Depth Look at Bristol-Myers Squibb
A close look at pharmaceutical company Bristol-Myers Squibb's last quarter, upcoming catalysts, and reasons to buy and sell the stock.
David Williamson owns shares of Pfizer. Max Macaluso, Ph.D. owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.